Skip to main content
SpringerLink
Log in

Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

This double-blind placebo controlled, parallel design clinical trial compared the therapeutic effects of the addition of lithium or placebo to haloperidol in 21 seriously ill state hospital patients with DSM-III-R schizophrenia, who did not have concurrent affective disorders and who had not responded to previous trials of conventional antipsychotic medication. During a baseline period of 6 weeks, patients were switched to a stable dose of haloperidol (mean ± SD dose=13.6±8.1 mg/day). Patients were then randomized to receive either lithium or placebo in addition to haloperidol for 8 weeks (mean ± SD lithium level =0.98±0.13 mEq/1). Symptoms and side effects were assessed weekly. Improvement in symptoms correlated with the non-blind adjustment of antipsychotic dose, but not with lithium or placebo treatment. Side effects ratings did not differ between the two groups, but one patient developed a reversible delirium associated with combined lithium/haloperidol treatment. For these long-term, severely ill patients, combined treatment afforded no advantage over treatment with haloperidol alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Addonizio G (1985) Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. J Clin Psychopharmacol 5:296–298

    PubMed  Google Scholar 

  • Addonizio G, Susman VL (1991) The neuroleptic malignant syndrome: a clinical approach. Mosby Year Book, St Louis, MO

    Google Scholar 

  • Alexander PE, Van Kammen DP, Bunney WE (1979) Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 136:282–287

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, revised (DSM-III-R) American Psychiatric, Washington, DC

    Google Scholar 

  • Andreason NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–788

    PubMed  Google Scholar 

  • Baastrup PC, Hollnagel P, Sorensen R, Schou (1976) Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 23:2645–2646

    Article  Google Scholar 

  • Baldessarini RJ (1985) Antipsychotic agents. In: Baldessarini RJ (ed) Chemotherapy in psychiatry: principles and practice. Harvard University Press, Cambridge, MA, pp 14–92

    Google Scholar 

  • Barklage NE, Jefferson JW (1987) Alternative uses of lithium in psychiatry. Psychosomatics 28:239–244, 249–253, 256

    PubMed  Google Scholar 

  • Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676

    PubMed  Google Scholar 

  • Biederman J, Lerner Y, Belmaker RH (1979) Combination of lithium carbonate and haloperidol in schizo-affective disorder. Arch Gen Psychiatry 36:327–333

    PubMed  Google Scholar 

  • Cade JFJ (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2:349–352

    Google Scholar 

  • Carman JS, Bigelow LB, Wyatt RH (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42:124–128

    PubMed  Google Scholar 

  • Christison GW, Kirch DG, Wyatt RJ (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 17:217–259

    PubMed  Google Scholar 

  • Cohen WJ, Cohen NH (1974) Lithium carbonate, haloperidol and irreversible brain damage. JAMA 230:1283–1287

    Article  PubMed  Google Scholar 

  • Cooper TD, Simpson GM (1976) The 24-hour lithium level as a prognosticator of dosage requirements. Am J Psychiatry 133:440–443

    PubMed  Google Scholar 

  • Delva NJ, Letemendia FJJ (1982) Lithium treatment in schizophrenia and schizo-affective disorders, Br J Psychiatry 141:387–400

    PubMed  Google Scholar 

  • Del Zompo M, Bocchetta A, Burrai C, Melis M, Corsini GU (1984) Lithium treatment in schizoaffective patients. In. Corsini GU (ed) Current trends in lithium and rubidium therapy. MTP Lancaster, England, pp 143–150

    Google Scholar 

  • Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 9:504–527

    PubMed  Google Scholar 

  • Folstein MF, Folstein SW, McHugh PR (1975) Mini-mental state: a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  Google Scholar 

  • Gershon S, Yuwiler A (1960) Lithium ion: specific psychopharmacological approach to the treatment of mania. J Neuropsychiatr 1:229–241

    PubMed  Google Scholar 

  • Goldney RD, Spence ND (1986) Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 143:882–884

    PubMed  Google Scholar 

  • Growe GA, Crayton JA, Klass DB, Evans H, Strizich M (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136:454–455

    PubMed  Google Scholar 

  • Hirschowitz J, Casper R, Garver DL, Chang S (1980) Lithium response in good prognosis schizophrenia. Am J Psychiatry 137:916–920

    PubMed  Google Scholar 

  • Kane JM (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 160 [suppl. 17]:41–45

    PubMed  Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796

    PubMed  Google Scholar 

  • Lewis HA, Bacher NM, Field PB (1986) Addition of lithium to neuroleptic treatment in chronic schizophrenia (letter). Am J Psychiatry 143:262

    Google Scholar 

  • National Institute of Mental Health (1974) Abnormal involuntary movement scale. DHEW Publication (ADM) 9-117, Rockville, MD

  • National Institute of Mental Health (1987) Systematic assessment for treatment of emergent events. DHEW Publication (ADM) 9-112, Rockville, MD

  • Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47 [Suppl]:3–11

    Google Scholar 

  • Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812

    Google Scholar 

  • Pickar D, Owen RR, Litman RE (1991) New developments in the pharmacotherapy of schizophrenia. In: Tasman A, Goldfinger SM (eds) Review of psychiatry, Volume 10. American Psychiatric, Washington, DC, pp 98–115

    Google Scholar 

  • Prakash R (1985) Lithium-responsive schizophrenia: case reports. J Clin Psychiatry 46:141–142

    PubMed  Google Scholar 

  • Prakash R, Kelwata S, Ban TA (1983) Neurotoxicity with combined administration of lithium and a neuroleptic. Comp Psychiatry 23:567–571

    Article  Google Scholar 

  • Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19

    Google Scholar 

  • Small JG, Kellans JJ, Milstein V, Moore J (1975) A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132:1315–1317

    PubMed  Google Scholar 

  • Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R—patient edition (SCID-P, Version 1.0). American Psychiatric, Washington, DC

    Google Scholar 

  • Wilson WH (1989) Diagnostic consultation to a state hospital. Hosp Commun Psychiatry 40:1290–1293

    Google Scholar 

  • Wilson WH (1992) Clinical review of clozapine treatment in a state hospital. Hosp Commun Psychiatry 43:700–703

    Google Scholar 

  • Zemlan FP, Hirschowitz J, Sauter F, Garver DL (1984) Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry 144:64–69

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Health Sciences University, Portland Oregon, and Dammasch State Hospital, Wilsonville, OR, USA

    William H. Wilson

Authors
  1. William H. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by Grant MH 46700 from the National Institute for Mental Health. Lithium and lithium placebo capsules were supplied by Lilly Pharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilson, W.H. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Psychopharmacology 111, 359–366 (1993). https://doi.org/10.1007/BF02244953

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02244953

Key words

Search

Navigation